Gradation of unstable angina based on a sensitive immunoassay for serum creatine kinase MB

Hans Erik Bøtker, Jan Ravkilde, Peter Søgaard, Poul Jørgen Jørgensen, Mogens Hørder, Kristian Thygesen

Abstract
A newly developed, highly sensitive immunoassay for creatine kinase MB isoenzyme was evaluated in 68 patients with or without different types of ischaemic heart disease. Patients were classified on the basis of clinical criteria in four groups: no ischaemic heart disease, stable angina, unstable angina, and acute myocardial infarction. Enzyme concentration in patients with stable angina was the same (even during exercise) as seen in the patients without ischaemic heart disease. Patients with unstable angina, however, could be divided into two groups. One group showed clear evidence of severe myocardial ischaemia by serial changes and higher mean values of creatine kinase MB up to 40 hours after the onset of symptoms, whereas in the remainder values were stable and resembled those seen in the patients without ischaemic heart disease. The changes in concentration correlated with signs of repetitive ischaemic episodes deduced from continuous ST segment monitoring during the first 24 hours after admission. These findings indicate that patients with unstable angina are a heterogenous group. In some, severe and prolonged ischaemia can be detected by a serological assay with high sensitivity.

We evaluated a newly developed, highly sensitive immunoassay for the creatine kinase isoenzyme MB in patients with ischaemic heart disease, with a view to classifying their disease on the basis of biochemical evidence of slight myocardial damage.

Patients and methods
PATIENTS
The study population consisted of 68 patients divided into four groups: 23 patients without ischaemic heart disease (group 1); 10 patients with stable angina pectoris (group 2); 21 patients with unstable angina (group 3); and 14 patients with acute myocardial infarction (group 4). The patients without ischaemic heart disease and patients with stable angina attended our outpatient clinic. Patients with stable angina were taking antianginal agents (long acting nitrates, calcium antagonists, or β blockers, or a combination of these drugs). Patients with unstable angina and acute myocardial infarction were recruited after admission to the coronary care unit within 12 hours of the development of retrosternal pain at rest. The mean time from onset of chest pain was 4 h 10 min (range 55 min–10 h 30 min) in patients with unstable angina and 3 h 35 min (range 1 h–10 h 30 min) in patients with acute myocardial infarction.

Eight (38.1%) of the 21 patients with unstable angina had not previously had symptoms of ischaemic heart disease. Thirteen patients (61.9%) had well established ischaemic heart disease—chronic stable angina in 12 (57.1%) and/or previous myocardial infarction in nine (42.9%). Among these, five patients were treated with nitrates, one with a β blocker agent, three with calcium antagonists, and two with a combination of β blockers and calcium antagonists.

Six (46.2%) of the patients with acute myocardial infarction had previously had symptoms of ischaemic heart disease: five had chronic stable angina and four an earlier myocardial infarct. One patient was treated with nitrates, two patients with calcium antagonists, and two patients with β blockers.

Patients admitted to hospital with unstable angina and acute myocardial infarction were treated with bed rest and control of cardiac pain by nitrates, morphine, and oxygen. No patient had haemodynamic disturbances or arrhythmias that required medical treatment. During the period of blood sampling aspirin treatment was started in all patients. Four patients with acute myocardial infarction started taking diltiazem and five others were
treated with intravenous glyceryl trinitrate. All the patients with unstable angina were treated with diltiazem and seven were given intravenous glyceryl trinitrate. A maximum of 480 ml of glyceryl trinitrate was infused in 24 hours. Treatment did not influence the interpretation of the analytical results because in each patient the concentration of serum albumin remained constant within the study period.

Informed consent was obtained from each patient and the study was approved by the regional scientific ethics committee.

**DIAGNOSTIC CRITERIA**

Group 1 (no ischaemia) comprised patients without a history of chest pain and without electrocardiographic signs of ischaemia both at rest and during exercise. Patients in group 2 (stable angina) had typical attacks of chest pain provoked by physical exertion or psychological factors that were relieved by glyceryl trinitrate. The diagnosis was confirmed by a positive exercise test during which chest pain was provoked along with at least 0.1 mV ST depression. Unstable angina (group 3) was diagnosed on the basis of chest pain at rest or brought on by minimal exertion and/or an entirely new pattern of chest pain in patients previously classified as having chronic angina. ST depression or T wave inversion were not obligatory; none had signs of myocardial infarction. Conventional serum creatine kinase B residual activity (that is after removal of MM and part of MB) was within normal range (<12 U/l) throughout the period of measurement. The diagnosis of acute myocardial infarction was based on the criteria of the World Health Organisation—that is, characteristic chest pain, unequivocal signs of infarction in the electrocardiogram, and a characteristic increase in enzyme activity of serum creatine kinase B and lactate dehydrogenase.

**PROCEDURE**

After informed consent was obtained, long acting antianginal medication was stopped a week before the study in the patients with stable angina. The patients without ischaemic disease and with stable angina were exercised on bicycles—until exhaustion in patients without ischaemia and until both pain and ST depression of at least 0.1 mV occurred in patients with stable angina. Blood samples were drawn before and every 3–6 hours up to 24 hours after exercise. Blood samples were drawn from patients with acute myocardial infarction and unstable angina on admission and every 3–6 hours during the first 24 hours and then every eight hours up to 72 hours.

**BLOOD SAMPLING**

Samples were drawn into tubes without anticoagulant through a catheter permanently placed in an antecubital vein. The samples were stored at +4 C for 15 minutes and then centrifuged at 3000 g for 10 minutes. The serum was stored at −21 C until analysis.

After thawing the serum was again centrifuged to remove any precipitate.

**ANALYTICAL METHODS**

The creatine kinase (EC 2.7.3.2) isoenzyme MB was measured by a newly developed and specially designed highly sensitive enzyme labelled immunosorbent assay (NovoClone CK–MB, Novo Biolabs, Cambridge, United Kingdom). Serum samples were simultaneously incubated with CK-B-specific antibodies attached to the polystyrene surface of the wells in a microtitration plate and with CK-M-specific antibodies conjugated with peroxidase. After one hour’s incubation the microtitration plate was washed to remove non-adherent components and the remaining peroxidase activity was measured by an end point assay with orthophenyl diamine as the substrate. The incubation time was 15 minutes and the absorbance was read on an Archimedes plate reader (Novo, Copenhagen). We established a calibration curve using samples with concentrations of 1–30 μg/l. All controls, calibration samples, and clinical samples were analysed in quadruplicate and the figures averaged to minimise variability. Specimens containing more than 30 μg of creatine kinase MB per litre were reassayed by the same assay with a wider range of detectability.

In a previous study of 315 outpatients (132 men and 183 women) without myocardial diseases the reference interval was 0–6 μg/l. The overall median of the log gaussian distribution was 1.91 μg/l (2.03 μg/l for men and 1.79 μg/l for women). Total and within assay coefficient of variance was less than 6% at the upper reference limit. The detection limit was 0.1 μg/l.

The serum concentration of the creatine kinase B subunit was measured by an homogeneous enzyme immunoassay after inhibition of creatine kinase M-subunit activity. Correction for residual adenylate kinase was done before we calculated the enzyme concentrations. For a creatine kinase B-subunit activity of 20 U/l the coefficient of variance was 5%.

**HOLTER MONITORING**

The ST segment was monitored in patients admitted to the coronary care unit with angina at rest. Recordings were taken from an anterior lead (CM5) and an inferior lead on magnetic tapes (Tracker recorder, Reynolds Medical, England). Tapes from patients with unstable angina were analysed for ST segment changes at Reynolds Medical by computer. Significant ST segment depression was defined as a horizontal or downward sloping ST segment shift of >0.1 mV 0.08 s after the J point that persisted for more than 1 minute.

**STATISTICAL ANALYSIS**

We used Student’s t test to analyse the significance of difference between means and the F statistic for the significance between the variances. We used Fisher's exact test to measure the significance of association be-
between serum enzyme fluctuation and Holter analysis. p Values of < 0.05 were regarded as significant.

Results
PATTERNS OF CREATINE KINASE MB
Figure 1 shows the mean values of serum creatine kinase MB concentration every three hours during the first 24 hours after exercise in the patients without ischaemic disease and in those with stable angina and during the first 72 hours after the onset of chest pain in patients with unstable angina or acute myocardial infarction. Because there was no difference between the mean concentrations of serum creatine kinase MB in patients without ischaemic heart disease and patients with stable angina we considered groups 1 and 2 together. The patients (group 3) with unstable angina had a higher mean concentration than this combination group from 3–6 hours to 21–24 hours (p < 0.05). Patients with acute myocardial infarction had significantly higher creatine kinase MB concentration than those with unstable angina from 3–6 hours to 64–72 hours (p < 0.01).

To determine whether enzyme release occurs during exercise, serum concentrations of creatine kinase MB were measured before, immediately after, and one hour after an exercise test in patients without ischaemic heart disease and patients with stable angina. These concentrations resembled those measured 3–24 hours after exercise.

VARIABILITY OF SERUM CREATINE KINASE MB
There was considerable variation in the patients with acute myocardial infarction and in eight (38%) of the patients with unstable angina (fig 2). In the group with unstable angina 13 (62%) patients had almost constant values (p < 0.01). The time course of changing enzyme concentrations in seven of the eight patients with enzyme fluctuation was similar to the curves obtained from patients with acute myocardial infarction. One patient had a different time course because the serum concentration of creatine kinase MB increased somewhat throughout the period of investigation. This patient had prolonged periods of chest pain, but did otherwise not differ from the others.

In figure 3 the mean concentrations of serum creatine kinase MB in the eight patients with unstable angina and enzyme changes UA (+) and the 13 patients with unstable angina and no enzyme changes UA (−) are compared with concentrations in the combined group (no ischaemic heart disease + stable angina) and the group with acute myocardial infarction. The UA (+) group had significantly higher mean values than the combined group in the interval from 3–6 hours to 32–40 hours (p < 0.05). The UA (−) group did not differ from the combined group. The UA (+) group had a creatine kinase MB concentration curve that resembled that of the patients with acute myocardial infarction but the concentration was significantly lower in the interval from 3–6 hours to 32–40 hours (p < 0.05). There was an earlier peak of serum creatine kinase MB in the UA (+) group than in the patients with acute myocardial infarction.

COMPARISON WITH CREATINE KINASE-B
Figure 4 shows that the mean serum creatine kinase-B residual activity was similar in the UA (+) and UA (−) patients.
The presence of ischaemic heart disease was confirmed by either an exercise test or coronary angiography in all patients with unstable angina. No patients with unstable angina without enzyme changes had coronary events during their hospital stay. Two patients with unstable angina and enzyme changes later had an acute myocardial infarction during their hospital stay.

Discussion
The results of the present study indicate that the new creatine kinase MB immunoadsorbent assay is a promising diagnostic tool because it may help to determine the frequency and severity of myocardial ischaemic events in the different coronary syndromes. Until now, assessment of damage to the ischaemic myocardium by measurement of creatine kinase isoenzymes has mainly been based upon analysis of creatine kinase B by immunochemical methods or creatine kinase MB by electrophoretic or chromatographic methods. These methods are satisfactory for diagnosing acute myocardial infarction but they are less sensitive for monitoring continuing myocardial ischaemia. Creatine kinase MB specific enzyme linked immunoadsorbent assays have a high sensitivity. This method has been further improved by using a double antibody technique, which gives a highly specific and sensitive assay with a very low limit of detectability.

In the present study the group without ischaemic heart disease represents the background serum concentration of creatine kinase MB and the group with acute myocardial infarction the full extent of enzyme concentration when there is irreversible cell damage. So these two patient groups are ideal reference groups for the study of serum enzyme concentration in patients with angina pectoris.

Despite the fact that ischaemia of short duration, verified electrocardiographically, was induced by exercise serum creatine kinase MB concentrations in the group with stable angina resembled those in the group without ischaemic heart disease. This indicates no enzyme leakage after a transient ischaemic attack in patients with chronic stable angina. Similar results have been reported by others.

In the group with unstable angina, however, our results indicate that the grade of unstable angina may reflect the degree of myocardial damage. Some of the patients with unstable angina showed clear evidence of ischaemic injury—serial changes and higher mean values of serum creatine kinase MB concentration—after the onset of symptoms than a reference group of patients without ischaemic heart disease or with stable angina. In addition, fluctuations in serum creatine kinase MB correlated with evidence of repetitive ischaemic episodes on continuous ST segment monitoring during the first 24 hours after admission.

Whether enzyme release is due to minor necrosis of myocardial tissue or severe but reversible ischaemic injury cannot be determined from the present study. Enzyme leakage has been found under experimental conditions in ischaemically damaged myocardial tissue without signs of irreversible myocardial injury. On the other hand, studies of patients suggested that slight increases in serum concentrations of creatine kinase and creatine kinase B were caused by micro-necroses. This is supported by techniques such as myocardial scintigraphy with technetium-99m-pyrophosphate and necropsy studies.

In patients with unstable angina serum creatine kinase MB concentrations were only slightly raised and the time course of the increase in creatine kinase MB resembled the curves obtained from patients with acute myocardial infarction. This suggests that patients with unstable angina had minimal myocardial necrosis. The earlier rise in peak creatine kinase MB in unstable angina resembled the enzyme course described in patients with non-Q wave infarction and has led to the hypothesis that reperfusion is likely to occur in patients with non-Q wave acute myocardial infarction. Reperfusion is also likely to occur after transient non-perfusion in unstable angina. However, the UA (+) patients did not have acute myocardial ischaemia by the classic World Health Organisation criteria. Findings were similar when serum myoglobin was used as a marker of myocardial ischaemia in a group of patients with an acute ischaemic myocardial insult. Therefore the gradation of patients with unstable angina implies the identification of a subgroup with small size myocardial damage.
of myocardial ischaemia need not be restricted to conventional myocardial infarction. It also reflects—in time and degree—the range of ischaemic damage of myocardial tissue. In this context the present results confirm that myocardial infarction and enzyme release are not all-or–no processes, but rather a continuum dependent on the duration and intensity of ischaemia and on the condition of the myocardium at the onset of the ischaemic episode.26–28

The subgrouping of patients in a study of this type is crucial. Unstable angina was diagnosed on clinical grounds and acute myocardial infarction was excluded by conventional enzymatic methods and electrocardiographic findings. Though the term unstable angina includes a wide range of patients with ischaemic heart disease the term has been clinically defined. To improve the understanding of this complex clinical entity, Braunwald recently proposed a clinical classification of unstable angina.29 This classification is based on the severity of angina—new onset of severe angina or accelerated angina, angina at rest within the past month but not within the preceding 48 hours, and angina at rest within 48 hours. These three grades of severity are classified further on the basis of the development of angina in the presence of extracardiac conditions that intensify myocardial ischaemia, develop in the absence of extracardiac conditions, or develop within two weeks after acute myocardial infarction. According to this classification all patients with unstable angina in the present study had primary unstable angina (group IIIB) because they presented with angina within 48 hours in the absence of extracardiac conditions. Half of a similarly defined group of patients with unstable angina had raised concentrations of serum myoglobin.26 This accords with our finding raised concentrations of serum creatine kinase MB in 38% of the patients.

Coronary events occurred only in the patients with unstable angina who also had raised serum creatine kinase MB. This increase in serum creatine kinase MB may be an additional prognostic factor in patients with unstable angina. This point adds further support to the view that patients with unstable angina and raised creatine kinase MB activity have areas of myocardial necrosis.

The highly sensitive creatine kinase MB immunossay is a promising means of extending our knowledge of the severity of myocardial ischaemic events in the different coronary syndromes. Application of the method is not restricted to conventional myocardial infarction. It is able to reflect—in time and degree—the range of ischaemic damage in myocardial tissue. The different time courses of creatine kinase MB activity in various patient groups in the present study show that the acute ischaemic syndrome—comprising unstable angina, acute myocardial infarction, and sudden ischaemic death—represents a continuum of ischaemic myocardial damage. It is tempting to suggest that the difference between no enzyme release and minimal enzyme release reflects a separation between stable and dynamic ischaemic conditions; if so the “dividing line” would fall within unstable angina.
